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Abstract 
 
Suppression of Neurodegenerative Symptoms via Suppressor of levy Mutation in Drosophila 
melanogaster  
 
 
Mutation of the levy gene on chromosome 2 of Drosophila melanogaster has previously 
been shown to cause temperature-induced paralysis and neurodegeneration. The Suppressor of 
levy mutation, Su(levy), also on chromosome 2, modulates the effects of the levy mutation and 
partly rescues the wild-type phenotype. The goal of this research was to determine if Su(levy) 
mutation alleviates the effects of neurodegeneration caused by mutations associated with 
Alzheimer’s and Parkinson’s diseases in humans. The mutant genes used were hLRRK2, α-
Synuclein, DJ1-α, Pink, Parkin, and Aβ-42. To determine this, flies carrying the above-
mentioned mutant genes were crossed with flies carrying Su(levy) to produce progeny carrying 
both mutations. The lifespan and locomotor abilities of these progeny were then tested and 
compared to control and mutant flies. The flies were also tested for their response to 
environmental toxins introduced to their diet. Our results show that in many cases the Suppressor 
of levy mutation plays a considerable role in alleviating neurodegenerative symptoms in 
Drosophila. Flies carrying Su(levy) show a significant improvement in lifespan, climbing ability, 
resistance to paralysis, and resistance to environmental toxins. 
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I. Introduction 
 
1.1 Human neurodegenerative disorders 
 
Human neurodegenerative conditions are characterized by progressive loss of neurons 
usually leading to cognitive, physical, and behavioral defects that often end in death [1]. The 
onset of such diseases is usually multifactorial, resulting from a combination of genetic 
mutations coupled with environmental factors [2]. Neurodegenerative disorders may be 
classified based on the type of neurons affected (such as dopaminergic neurons, motor neurons, 
etc.), the type of pathology exhibited (such as movement disorders, memory loss, dementias, 
etc.), and by the origin of the disease (genetically inherited, environmental, etc.) [3]. Many 
human neurodegenerative disorders are late onset and affect only aging members of the 
population. Most common among these are Alzheimer’s disease (AD), Parkinson’s disease (PD), 
and Fronto-temporal dementia (FTD). Evidence shows that neurodegenerative diseases may be 
passed on in a familial manner from parent to child, but over 90% of cases are sporadic and not 
related to familial inheritance [4,5]. There does not seem to be a racial or ethnic bias toward 
inheriting this family of diseases, and the single most abundant risk factor seems to be age. 
Although there is widespread occurrence of neurodegenerative disease in the United States, the 
actual mechanisms underlying their function is not well understood. 
Human neurodegenerative diseases unmistakably are devastating to their victims both 
physically and psychologically. What often goes unrecognized are the emotional and financial 
burdens carried by the families and loved ones of the victims. A conservative estimate holds that 
in the next 15 years, over 8 million Americans will develop Alzheimer’s disease, and yearly 
costs are already in the hundreds of billions [6]. This does not even take into account the income 
lost by caregivers who need to leave their jobs to provide 24-hour care for family members—a 
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cost estimated to be at 220 billion dollars yearly [6]. As of yet the therapeutic treatments are still 
lacking and what few drugs that are on the market are very limited in their effectiveness. This is 
due in large part to a lack of understanding of the actual biochemical mechanisms behind such 
diseases. Significant research is currently being done on such model organisms as fruit flies and 
mice in order to elucidate these mechanisms and hopefully improve upon current treatments. 
On a cellular level, most neurodegenerative diseases are characterized by a buildup of 
amyloid protein plaques and neurofibrillary tangles in portions of the brain [7]. The 
physiological implications of this are typically motor or cognitive impairment, caused by the 
degradation of, or improper functioning of neurons; most commonly dopamine-related or 
dopaminergic neurons [1]. The phenotypic effects may manifest themselves in memory loss 
(Alzheimer’s), impaired motor coordination (Parkinson’s), and speech and emotional impairment 
(FTD) among other things. 
Besides AD and PD, there are dozens of other lesser-known neurological disorders 
prevalent in the human population. These include Amyotrophic Lateral Sclerosis (ALS), Motor 
Neuron diseases, Trinucleotide Repeat disease, Leigh Syndrome, Huntington’s disease, and 
Fragile X Syndrome, to name a few [8]. They exhibit a wide array of symptoms including mental 
retardation, ataxia, muscle atrophy, loss of balance, tremors, and behavioral abnormalities [3]. 
Although an exhaustive overview of the mechanisms behind these diseases would be extremely 
worthwhile, for the purposes of this paper, AD and PD will be the neurological disorders of the 
greatest focus. 
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1.2 Alzheimer’s Disease 
AD is the most prevalent neurodegenerative disorder in the United States, affecting 
roughly 1% of the population over 65 and roughly 30% of the population over 85 [9]. It is 
considered a disease of old age, and as such, as the average life expectancies continue to rise in 
this country, the physical, emotional, and financial burdens placed on patients and families will 
reach epidemic proportions. Currently, it is estimated that 5.2 million Americans have AD. With 
the discovery of causative environmental agents in addition to genetic factors, it is currently 
projected that by the year 2050, this number will rise to over 14 million. It is the 6th leading 
cause of death in this country, and it is estimated that it cost the nation $203 billion in the year 
2013 [9]. 
The significant majority of AD cases (95%) are idiopathic or sporadic, meaning that there 
is no genetic component to them [4]. Though occurring much less frequently (about 5% of the 
total cases), hereditary or familial cases of AD have yielded substantial insight into the 
mechanism behind its formation. These cases are designated as Familial Alzheimer’s Disease, or 
FAD. These familial cases of AD can provide insight into the mechanisms behind Alzheimer’s, 
and as such, they have been the target of the majority of research. Currently, three “causative” 
gene defects have been identified in human early onset AD (early onset being characterized as ˂ 
60 years) [10]. These include Aβ, APP, and the PSN family; mutations that have been shown to 
contribute to plaques and neurofibrillary tangles [11]. It is these familial inheritance cases that 
will provide the most insight into the actual pathways involved in neurodegenerative disorders.  
Symptomatically, AD first manifests itself with short-term memory loss, escalating to 
loss of “executive” functions, and in worst case scenarios, full-on dementia [8]. The brain of 
Alzheimer’s patients is characterized by the significant degeneration of the cortex and 
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hippocampus; regions associated with learning and memory [8]. Additionally, there are two 
classic features seen upon histological sectioning of an AD brain; extracellular β-amyloid 
plaques [12] and intracellular neurofibrillary tangles (NFTs) [13]. Essentially, β-amyloid plaques 
are protein deposits that accumulate in the brains of AD patients. The β-amyloid plaques are rich 
in Aβ40 and Aβ42 peptides, with Aβ42 thought to be the more deleterious of the two. They are 
formed by the proteolytic processing of β-amyloid precursor protein (APP), which will be 
discussed in greater detail later. NFTs are essentially little knots and tangles that occur in central 
nervous system neurons. These NFTs have been found to be rich in TAU, a protein associated 
with microtubule formation [14]. Curiously, these protein deposits can be found in different 
diseases, such as PD or MND, but in various different neurons. As a result, the identification of 
these characteristic buildups has not yielded much in the realm of a mechanistic understanding of 
how they are related to disease. 
 
1.3 Parkinson’s Disease 
Parkinson’s disease is the most prevalent neurodegenerative movement disorder, with 4-6 
million cases diagnosed worldwide [11]. PD is characterized by tremors, rigidity, slow 
movements, and loss of balance. PD has an average onset age of 70, although there are a fair 
amount of cases (4%) that are considered early onset, occurring before age 50 [11]. The mean 
amount of time from diagnosis to death is 15 years, although several other factors may be at play 
[15]. Since PD is a progressive neurodegenerative condition, it is often difficult to determine the 
actual cause of death. Much like with AD, the vast majority of PD cases are idiopathic, most 
likely caused by a variety of environmental or genetic factors. There is no apparent racial or 
ethnic risk factors, with age being the only consistent culprit. Inherited or familial forms of the 
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disease account for roughly 10% of all the cases but show very similar features [16]. Though few 
in number, these cases yield a wealth of information pertaining to genetic inheritance of PD. 
Several loci have been implicated in the pathogenesis of Parkinson’s, most notably α-synuclein. 
These specific gene mutations will be discussed in detail in the section on Materials and 
Methods.  
As with AD, there are some characteristic features associated with PD as it pertains to the 
nervous system. The most notable pathological change is the progressive breakdown of 
dopaminergic neurons in the substanta nigra and locus cereoulus of the brain; both regions of the 
midbrain associated with movement [13]. This loss of neuronal functioning is the direct cause of 
movement disorders observed in PD. Another feature common in PD is the accumulation of 
Lewy bodies, which are essentially abnormal aggregations of proteins that accumulate in the 
nervous tissue. In the case of PD, these Lewy bodies are principally comprised of the protein α-
synuclein [17]. As well as Lewy bodies, there are two other characteristics commonly associated 
with PD; oxidative damage, and mitochondrial dysfunction [18]. Though these are not 
necessarily causative agents, they are common occurrences associated with this disorder. 
For the bulk of neurodegenerative diseases, the molecular mechanisms behind the disease 
are not well understood. There are currently a lack of effective treatments, and a complete 
absence of preventative measures for the disorders. The most commonly prescribed drugs are L-
Dopa and Acetylcholinesterase inhibitors, for PD and AD, respectively [19]. They are reactive in 
nature, however, and provide only symptomatic relief without addressing the underlying cause of 
the disease. As such, an understanding of how these disorders work on a molecular level is 
necessary to develop new and novel treatments for them. 
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1.4 The role of Mitochondrial dysfunction in Neurodegenerative Disorders 
In recent years, there has been increasing evidence for the role of mitochondrial 
involvement in neurodegenerative disorders [20]. Many studies have shown a correlation 
between ND and impaired electron transport chain function, particularly the function of iron-
containing cytochromes associated with movement over the mitochondrial membrane [20,21]. 
As a result of this dysfunction, there is an increase in the amount of free radicals, which are 
harmful to the proper functioning of a cell. 
Increasingly, evidence has pointed to oxidative stress, and in particular to reactive oxygen 
species (ROS), as a culprit for these mitochondrial dysfunctions. In common terms, oxidative 
stress refers to a cell’s increased production of oxidizing species, such as hydrogen peroxide, 
H2O2, or superoxide O2
- [21]. These species are more commonly referred to as free radicals, or 
atoms containing unpaired electrons. They are known for wandering the cell and covalently 
bonding with anything they can find, very often forming dimers with other free radicals. These 
radicals are naturally produced as a byproduct of respiration, and in moderation are, in fact, 
harmless. However, when generated in high quantities, they can be extremely detrimental to the 
proper functioning of cells. They have been implicated in everything from deformation of ion 
channels in the membrane, to inducing apoptosis, to disrupting DNA transcription by inhibiting 
critical transcription factors [21].  
In properly functioning mitochondria, excess free radicals are scavenged up by enzymes, 
such as peroxidase. However, when ROS build up, they interact with membrane lipids and 
proteins, altering their conformations and ultimately disrupting their function. In the context of 
AD, disruption of the Aβ peptide causes neurofibrillary tangles that are the hallmark of the 
disease [22].  
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1.5 Drosophila as a model organism  
The common fruit fly, Drosophila melanogaster, has been used for a century as a model 
organism for laboratory study, particularly in genetics [23]. Thomas Hunt Morgan, the scientist 
responsible for much of the pioneering work on Drosophila in the early 1900s, was first attracted 
to the fact that they have a reasonably short life cycle (10 days at 25°C), and produce a 
substantial number of progeny (upwards of 100 eggs per female) [23]. This allows large-scale 
testing and high throughput analysis to be simple and performed in a short amount of time, 
yielding significant amounts of data [23]. The lifespan is typically 40-120 days but can be easily 
manipulated by altering conditions such as temperature, food source, and amount of stress [24]. 
Relative to other lab organisms such as the mouse or rat, Drosophila can yield a wealth of 
information in a much shorter amount of time. Also, due to the very cooperative nature of 
Drosophila researchers, there are an abundance of online information and databases available, 
with several avenues for obtaining various strains of Drosophila. As a result, it is extremely easy 
and cheap to obtain Drosophila, making it a very attractive choice for study.   
Ostensibly the fruit fly looks fairly primitive in physiology and behavior. However, it 
actually demonstrates complex behavior, including such things as learning and memory, and has 
a rather sophisticated brain [25]. The genetic makeup, development, anatomy, and behavior of 
Drosophila has been very well characterized over the last 100 years, allowing for extensive study 
of molecular and biological processes [26].  The fruit fly has 13,600 genes in its genome, or 
roughly half of the 27,000 genes that comprise the human genome [27]. These are housed in four 
pairs of chromosomes, with the first chromosome acting as the sex-determiner much like in 
humans. Several years of research have contributed to the multitude of genetic “tools” that allow 
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for Drosophila study, including such things as transgenic flies, GAL-4 constructs, P elements, 
and differential gene expression [28, 29]. 
Finally, and perhaps most importantly, Drosophila has proven to be a great organism for 
modeling human neurodegenerative conditions [28]. It has been shown that roughly 75 % of the 
molecular pathways in humans that are implicated in disease show a great deal of sequence 
conservation in Drosophila at the protein level [30]. Not only disease-associated genes, but many 
molecular pathways including cell signaling and the regulation of cell cycle and growth are 
conserved across the species [31]. In layman’s terms, the genetic sequences that code for certain 
proteins in Drosophila are very similar to those that exist in Homo sapiens. Consequently, 
disease models in Drosophila can be very useful in obtaining information on the biochemical 
level as to the mechanisms behind human ND disorders [8]. 
 
1.6 Genetic tools available for Drosophila work 
As mentioned above, Drosophila makes for a great model organism due to the 
availability of several genetic tools and techniques. One of the fundamental aims in the study of 
neurodegeneration is to identify the underlying molecular pathways that cause the 
neurodegeneration. This allows for the development of targeted treatments, specific to the 
problem at hand. Drosophila provides a great medium for performing genetic studies aimed at 
understanding these mechanisms. 
One of the most common practices used to identify disease pathways is the over-
expression or under-expression of a human disease gene in Drosophila. This can be done with 
both wild type genes and mutant human genes. The location and timing of gene expression can 
be controlled by UAS-GAL 4 system, which will be discussed in greater detail later. In short, 
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this system allows for the controlled expression of a given gene (responder) in a specific tissue 
(driver) of choice, allowing the researcher to control the expression of the gene [32]. There are 
some drawbacks to this approach. The GAL-4 protein itself can cause neurodegeneration if it is 
present in excess, and the degree of severity of a given neurodegenerative phenotype may not be 
commensurate with the amount of protein expressed.  
Another technique commonly used is gene knockouts and knockins. This allows a given 
Drosophila gene to be ‘turned off’ or ‘turned on,’ and the resultant phenotype to be analyzed. 
Inactiviation can be achieved through means such as DNA methylation, interfering RNAs, or 
mutational inactivations. Gene overexpression is performed (typically through a GAL-4 system) 
in order to study gain-of-function scenarios. Once a gene’s expression is altered, the progeny can 
be screened for the presence of neurodegenerative phenotypes [32]. 
Once a given phenotype has been identified, it is often followed by a screen for enhancers 
and suppressors. This is often done by inducing mutations through the feeding of ethyl methane 
sulfonate (EMS) and propagating any flies that show worsening of the mutant phenotype 
(enhancer) or rescue of the wild-type phenotype (suppressor). This is exactly what occurred in 
the case of Suppressor of levy. Once the levy gene mutation was identified, mutations were 
induced using EMS, and progeny that did not show neurodegeneration were isolated and 
propagated. The focus of this study, Supressor of levy mutation, was recognized as rescuing 
wild-type phenotypes in neurodegenerative levy flies. As a result, this gene became the basis for 
our research. 
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II. Background 
2.1 The levy mutation 
The basis for this research started with the identification of the levy mutation in the lab of 
Satpal Singh, PhD at the University at Buffalo. The mutation was identified by using a forward 
genetics approach using temperature-induced paralysis as the basis for identification. Mutations 
were induced by using ethyl methane sulfonate as described by Ashburner [32]. Flies were then 
exposed to 38°C for a period of 5 minutes, which led to paralysis of certain mutant flies, which 
were then propagated. One of these mutations were designated as levy. Deficiency mapping and 
P elements were then used to localize the mutation, which was subsequently sequenced [33]. 
The levy mutation was mapped to the right arm of chromosome 2. The mutated gene 
corresponded to the gene CG17280 as designated in the flybase database [34]. It codes for 
subunit VIa of the cytochrome C oxidase, a protein complex critical in the normal functioning of 
mitochondrial biochemical pathways [33]. Mitochondrial misfunction has been linked to 
neurodegeneration and several neurodegenerative diseases, including Parkinson’s and 
Alzheimer’s. In addition to temperature-induced paralysis, the levy mutation causes 
encephalomyopathic effects, reduced ATP generation, reduced lifespan, and reduced motor 
recovery after mechanically-induced shock (bang-sensitivity) [33].  
 Figure 1 shows the reduced lifespan characteristic of levy flies. The percentage of 
surviving flies grown at 29°C is shown as a function of time. Wild-type flies (CS) lived to a 
median age of 28 days. Levy transformants (T) were generated by integrating the wild-type copy 
of the levy gene into the levy mutant genome using germline transformation. The transformants 
showed a similar lifespan to wild-type flies. The levy mutants (levy) and transformant controls 
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(Tc) both showed a median lifespan of roughly 8 days, which is a 70 % decrease in median 
lifespan [33]. 
 As mentioned above, flies exhibiting neurodegeneration show a reduced ability to recover 
from mechanically induced shock, a phenomenon termed “bang-sensitivity.” This is measured 
quantitatively by vortexing a vial of flies on high speed for ten seconds which paralyzes the flies. 
The length of time it takes for the flies to stand and begin moving again is then measured. Figure 
2 displays the bang-sensitivity of levy flies when compared to wild-type flies. The percentage of 
flies paralyzed is displayed as a function of time. Notice that twenty-day old levy flies (20d levy) 
and twenty-day old transformant controls (20d Tc) took significantly longer to recover than ten-
day old levy flies (10d levy) and ten-day old transformant controls (10d Tc). Two-day old flies 
did not show any significant bang-sensitivity [33].   
Upon histological cross-sectioning, the brain of a levy mutant fly shows a characteristic 
“swiss-cheese” effect commonplace in spongiform neurodegeneration [33]. Figure 3 shows a 
wild-type fruit fly brain (A) in cross-section as compared to a levy fly brain (B). The holes in the 
levy brain are characteristic of neuron cell degradation and death [33]. 
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                                 Lifespan analysis in levy flies 
                         
  
 
 
 
 
 
 
 
 
 
 
Figure 1: Lifespan of levy and wild-type flies. Levy flies (levy) and tranformant controls (Tc) 
show a significantly shorter median lifespan than wild-type flies (CS) and transformants (T) 
when grown under the same conditions [33]. 
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                                       Bang-sensitivity in levy flies 
                          
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Bang-sensitivity of levy flies and transformant controls. Flies showed age-dependent 
increases in sensitivity to mechanical shock as induced by vortexing [33]. 
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Figure 3: Cross-section of wild-type brain (A) compared to that of a levy fly brain (B). The 
small white holes in the levy brain are the result of neurodegeneration in the brain, a condition 
which leads to reduced lifespan and locomotor abilities [33]. 
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2.2 Suppressor of levy mutation 
Subsequent to the isolation of the levy gene, a mutation was discovered that suppressed 
the effects of levy and partially rescued a wild-type phenotype; that is, certain flies with the levy 
mutation did not exhibit the same neurodegenerative symptoms that the rest of the levy flies did. 
Something in these exceptions was preventing or suppressing the symptoms associated with the 
levy mutants. Accordingly, this mutation was called Suppressor of levy, notated Su(levy), and 
was subsequently mapped to the 2nd chromosome as well. This suppressor mutation was induced 
in the same fashion as levy, by feeding ethyl methane sulfonate to levy flies and screening for 
rescue upon exposure to 38°C. A complementation test was used to verify that it was in fact a 
novel and unique gene that was rescuing the wild-type phenotype, and not some mutation in the 
levy gene itself. These Suppressor of levy flies were propagated and balanced with CyO such that 
they would produce a stable line. One of the cornerstones of our research focuses on the 
following question: Since this Suppressor mutation rescues a wild-type phenotype in levy flies, 
might it also rescue wild-type phenotype in flies with other ND-inducing mutations? 
 
2.3 Selected genes of interest 
There are a number of genes that have been identified as either contributing to and/or 
being causative agents of familial PD. As is often the case, many of them have orthologs in the 
Drosophila genome. Table 1 shows the most commonly identified culprits in familial PD [3]. 
With the exception of α-synuclein, these genes all have orthologs in the Drosophila genome, 
making them very accessible for study. Table 2 shows some of the gene families associated with 
AD [3]. Our research focused primarily on five genes associated with PD; namely α-synuclein, 
DJ 1-α, LRRK2, Pink1, and Parkin, as well as one gene associated with AD; namely Aβ-42. 
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Table 1: Parkinson’s disease-associated genes [3] 
Gene/Protein Fly Ortholog Protein Function 
Alpha-synuclein None Pre-synaptic protein 
Parkin CG10523 E3 ubiquitin ligase 
UCH-L1 Uch/CG4265 E3 ubiquitin hydrolase/ligase 
PINK1 Pink1/CG4265 Mitochondrial kinase 
DJ-1 
DJ-1a/CG6646 
DJ-1b/CG1349 
Redox sensor/Chaperone 
LRRK2 lrrk2/CG5483 Kinase/GTPase 
HtrA2 HtrA2/CG8486 Mitochondrial pro-apoptotic protease 
GBA CG33090 Lysosomal enzyme 
POLG tamas/CG8987 Mitochondrial DNA polymerase 
Tau tau/CG31057 Microtubule stabilization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17 
 
                     Table 2: Alzheimer’s disease-associated genes [3] 
                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene/Protein Fly Ortholog Protein Function 
APP Appl/7727 Pre-synaptic protein 
PSN-1/2 dPs/CG18803 Gamma-secretase activity 
Tau tau/CG31057 Microtubule stabilization 
APOe4 None Lipid/cholesterol metabolism 
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2.3a: LRRK-2 
LRRK2 stands for leucine-rich repeat kinase, which is a gene associated with kinase 
production and GTP enzymatic function [35]. It is inherited in an autosomal dominant fashion, 
and has a well-conserved ortholog in Drosophila denoted LRRK2 (CG5483). LRRK2 mutations 
are the most common cause of Familial Parkinson’s Disease (FPD), accounting for nearly 40 % 
of FPD cases in certain populations [35]. The actual in vivo role of wild-type LRRK2 proteins is 
unknown at this point. Interestingly enough, overexpression of wild-type LRRK2 in Drosophila 
leads to cell death in vitro, most noticeably in dopaminergic neurons [35]. 
In terms of lifespan, overexpression of LRRK2 has no significant effect [35]. Interestingly 
enough, overexpression actually increased the fecundity of female flies, a surprising result given 
its seemingly deleterious nature in the brain. Locomotor ability varied with age of mutants as 
well as the particular LRRK2 mutation. In some cases, climbing was improved relative to the 
control, whereas in some cases it showed a significant decrease. An external phenotype 
consistent with all LRRK2 mutants seems to be eye defects. Particularly in males, LRRK2 flies 
show black lesions on the eyes, loss of pigmentation, and architectural defects that are 
particularly noticeable under electron microscope [35].  
Overall, overexpression of LRRK2 increased the rate of dopaminergic cell death [35]. 
Finally, LRRK2 mutants have been shown to interact with other recessive PD genes, including 
pink and parkin. 
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2.3b: DJ 1-α 
The DJ-1 gene in humans has been identified as an inherited PD gene, and its protein has 
been linked with chaperone function and protection from oxidative stress [36]. It has two 
orthologs in flies: DJ1-α (CG6646) and DJ1-ß (CG1349), each of the coded proteins sharing 
about 70% similarity with the human DJ1 protein.  
Much information has been learned about DJ1-α from doing double knockout 
experiments. Essentially, this involves deleting both the DJ1-α and the DJ1-ß genes from the 
DNA sequence so that protein production is blocked at the transcriptional level. Interestingly 
enough, in Drosophila, double knockout mutants of DJ1-α and DJ1-ß are both viable and fertile, 
and don’t show any noticeable phenotypic defects. Likewise, the double mutants show lifespans, 
fertility, viability, and dopaminergic neuron functionality all similar to what is found in wild-
type flies. As such, there appears to be no overt phenotypic defects in flies lacking the DJ1 
function [37]. However, these flies show significantly enhanced sensitivity to oxidative stress  
[37].  
 
2.3c: α-Synuclein 
Alpha-synuclein is a dominantly inherited gene that codes for a pre-synaptic neuronal 
protein of unknown function [38]. It has been shown that mutations in α-synuclein lead to 
neurodegeneration in familial PD cases. In particular, α-syn mutations cause loss of dopamine 
neurons, formation of Lewy bodies, and locomotor dysfunction [38]. There is no α-syn gene 
endogenous to flies. As such, animal models associated with α-syn mutations use human α-syn to 
generate transgenic Drosophila mutants through germline transformation. These transgenic flies 
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are thought to adequately model Parkinson’s symptoms that are seen in humans with α-syn 
mutations [37]. 
The expression of wild-type human α-syn in flies leads to normal development and 
functioning of neurons, histological appearance, and fly viability and behavior [38]. It is the 
expression of mutant A30P and A53T α-syn (α-syn proteins associated with PD) that shows 
symptoms of neurodegeneration. The degeneration and disappearance of dopaminergic neurons 
occurs in 30-60 day old flies expressing either A30P, or more notably, A53T α-syn. The only 
significant phenotypic differences in mutant flies that is observable with light microscopy lies in 
the retina of the eye. Overexpression of human α-syn in the eye leads to progressive retinal 
degeneration that is noticeable after 10 days, and is very distinct after 30 days [38]. This 
deviation in eye structure can be observed as a manifestation called the pseudopupil [39]. In 
terms of behavioral assays, one of the most telling features of mutant α-syn is their significantly 
decreased climbing ability. Compared to wild-type flies, all mutant strains of α-syn show 
markedly decreased ability to climb, particularly as they get older. This dysfunction is indicative 
of degeneration of dopaminergic neurons and formation of Lewy bodies in the cortex [38]. 
 
2.3d: Pink & Parkin 
Both Parkin and Pink1 are recessively inherited genes that code for a ubiquitin protein 
ligase and a mitochondrial kinase, respectively [3]. They are endogenous to both humans and 
Drosophila and show a significant degree of sequence similarity between the species. Parkin is 
shown to code for ubiquitin ligase proteins, used in several cellular functions, particularly 
conferring substrate specificity in ubiquitination pathways [40]. Pink1 codes for a mitochondrial 
kinase that is critical in the successful functioning of mitochondrial transport chains [41]. Both 
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Pink1 and Parkin mutant flies show remarkable similarity in terms of their phenotypes and 
behavior, and will therefore be discussed in concert.  
A fair amount of work has been done on parkin and pink1 null alleles. A null allele is 
essentially a mutation whereby the gene of interest has either been completely removed, or the 
protein that it codes for has been deactivated in some fashion. It has been shown that flies with 
null alleles for parkin and pink are viable, but exhibit several symptoms, both physical and 
behavioral, associated with neurodegeneration. First and foremost, the lifespan of null mutants is 
significantly reduced. Wild-type flies showed a median lifespan of 39 days and a maximum age 
of 75 days at 25°C, whereas null mutants showed a median lifespan of 27 days, with a maximum 
age of 50 days. Parkin mutants also show a downturned wing phenotype in both the homozygous 
and the heterozygous state. This phenotype is not fully penetrant, but does show up in roughly 40 
% of newborn flies, and in 70% of flies by age 10 days. As a result of this wing condition, many 
parkin flies show defects in flight and climbing ability.  This has been verified by expressing 
parkin in mesodermal tissue using a GAL-4 system. As a result, both flight and climbing abilities 
returned to wild-type status, showing that parkin is required for normal functioning of the 
musculature. Finally, parkin mutants show a distinct alteration of normal structure in 
dopaminergic neurons, upon histological examination. This is a finding consistent with other PD 
mutants, including α-syn. LRRK2, and DJ1-α. 
 
2.3e: Aβ-42 
The first gene that was identified as being a causative agent of AD is the gene coding for 
β-amyloid precursor protein, or APP, located on chromosome 21 [22]. Several different APP 
mutations have been characterized, all leading to the classic β-amyloid protein deposits, 
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specifically Aβ-42, found in the brain of AD patients. These aggregations of Aβ have been found 
to be toxic to neurons, and ultimately lead to neuronal cell death [10]. According to what has 
been termed the ‘amyloid hypothesis,’ accumulation of the Aβ 42 peptide initiates the pathogenic 
cascade in AD, including Tau hyperphosphorylation, aberrant cellular signaling, and ultimately, 
cell death [41]. Efforts to identify the underlying process of protein deposition in the brain have 
been aimed at categorizing the pathways involved in the movement of intracellular APP [43]. 
Defects in APP lead to several AD symptoms, including plaque deposition, defective axon 
transport, lack of synaptic plasticity, and vacuolization of the brain [3]. 
The ortholog in Drosophila is notated APPL, or APP-like gene, and is expressed in all 
neuronal tissue. Knock-out mutation of APPL in flies does not cause the same neurodegenerative 
phenotype found in humans. This is most likely because there is a lack of homology between 
human APP and fly APPL in the Aβ region, and as a result Aβ deposition does not occur in the 
flies. Therefore, Drosophila models use the GAL-4 system to overexpress human forms of Aβ in 
desired regions [3]. Although flies do not produce Aβ42 naturally, overexpression of human APP 
results in Aβ42 production and neuronal cell death [44]. 
 
2.4 The UAS-GAL-4 Driver system 
As mentioned above, the last 20 years has seen an explosion of powerful genetic tools 
being used with Drosophila. Perhaps one of the most ubiquitous techniques is the bipartite 
UAS/GAL 4 system used for targeted expression of genes in specific tissues.  
GAL4 is a gene that is endogenous to common yeast, S. cerevisae. It codes for a protein 
that is 881 amino acids long whose transcription is induced by galactose. The gene has been 
fairly well characterized due to many studies done on transcriptional activation in yeast. GAL4 
23 
 
has been shown to be a transcriptional activator in yeast by binding upstream of the promoter 
site, much like an enhancer would in animal cells.  These upstream sites are now commonly 
called Upstream Activating Sequences, or UAS. The beauty of this system is that the GAL4 gene 
will work in multiple different settings, regardless of the organism, as long as the UAS is 
present, and perhaps even more importantly, it seems to have no harmful effects on the organism. 
This is a very useful system particularly when dealing with genes with toxic or 
deleterious effects. For example, a harmful gene can be maintained in a silent, untranscribed 
state via a UAS in a parental fly line. Upon crossing with a line carrying a GAL4 driver for a 
particular tissue type, the progeny will express the UAS-linked gene in that target tissue only. 
For example, a UAS is inserted into a male fly upstream of a gene denoted ‘X,’ which codes for 
a protein producing red pigment. A GAL4 driver is inserted into a female fly with a gene denoted 
‘Y,’ which is expressed only in thoracic bristles. When these two parental lines are mated, the 
progeny will express both genes simultaneously. That is, the GAL4 driver will stimulate the 
production of red pigment from gene X (the responder) in the thoracic bristles. 
This can also be useful to induce the transcription of a deleterious responder gene in a 
region of interest. The resultant cell death or dysfunction can elucidate the role of the cells and 
the effect of the cell death on the organism as a whole. It may even shed light on the mechanisms 
behind how certain diseases or disorders work [45]. 
In this research, we use an APPL-GAL4 driver to induce activation of gene mutations 
associated with PD and AD via Upstream Activating Sequences. APPL stands for “APP-like” 
and is a Drosophila ortholog of the human APP gene, which stands for B-amyloid precursor 
protein. It is a gene that codes for a protein that functions pre-synaptically in neurons. The 
GAL4/UAS system is being used in this scenario to express proteins from various PD-related 
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and AD-related genes in the neurons. As such, the APPL-GAL4 driver needs to be combined 
with UAS-tagged PD and AD genes via selective crossing of parent lines. The subsequent 
progeny should show neurodegeneration as a result of these mutations being expressed in the 
CNS. Subsequently, the Su(levy) mutation can be crossed to determine if it shows rescue of wild-
type behavior in the PD and AD flies. 
 
2.5 The Goal of our research 
The purpose of this research is to determine if the Suppressor of levy gene alleviates 
neurodegenerative phenotypes in fly mutants other than levy; namely, Parkin, Pink1, DJ1-α, α-
synuclein, LRRK2, and Aβ42. These strains have all been shown to exhibit symptoms of 
neurodegeneration in one form or another. Reduced locomotor ability, including flight and 
climbing defects, are shown in Parkin, Pink, α-Syn, LRRK2, and Aβ-42 flies. Reduced longevity 
is shown in Parkin, Pink, and Aβ-42 flies. Increased sensitivity to environmental toxins is shown 
in DJ 1 flies [3]. It is the goal of this project to determine if combining Su(levy) with flies 
carrying these mutations will lessen these symptoms and rescue a wild-type phenotype. If this 
proves to be the case, further study into the mechanisms behind the rescue will become 
necessary, as there may be significant implications for the understanding of neurodegeneration in 
a human model.  
A future goal of this research is to identify and sequence the Suppressor of levy mutation, 
and to gain insight into the mechanisms behind its function. A mechanistic understanding of how 
Su(levy) alleviates neurodegenerative symptoms has therapeutic ramifications, potentially 
yielding information about the underlying functioning of human neurodegenerative diseases. 
Clearly, the absence of a gene product (or perhaps the production of a dysfunctional gene 
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product) coded for by the Su(levy) mutation is playing some role in alleviating the 
neurodegenerative symptoms in levy fruit flies. If a drug that mimics the role of the Su(levy) 
mutation (by blocking or otherwise inhibiting the gene product) could be produced 
pharmacologically, it may prove to be a promising step forward to the treatment of 
neurodegenerative disorders in humans. 
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III. Materials and Methods 
3.1 Fly strains and rearing: 
All flies used during this research were raised on a standard cornmeal medium with the 
exception of APPL-GAL 4 flies. They were raised on Carolina® instant Drosophila medium. All 
flies were grown and aged at 25°C with the exception of flies being used for lifespan analysis. 
They were aged at 29°C. In some instances, it was necessary to transfer flies to 18°C for a period 
of time for the purposes of virgin isolation. Canton Special (CS) flies were used as the wild-type 
for all experiments. The mutant strains levy and Su(levy) were provided by the lab of Satpal 
Singh, PhD, University at Buffalo Department of Toxicology and Pharmacology. The mutant 
AD and PD flies were obtained from the lab of Shermali Gunawardena, PhD, University at 
Buffalo Department of Biological Sciences. All crosses were performed in bottles at 25°C, with 
females and males being used in a roughly 2:1 ratio, respectively. Table 3 lists information about 
all of the strains of flies used for these experiments and Table 4 lists the specific AD and PD 
strains used for our research. The leftmost column of Table 3 provides the abbreviated notation 
for each strain. The middle column provides the complete genotype, and the rightmost column 
provides any specific phenotypic markers that were used for identification. Fly genotypes are 
written using specific notation (See Figure 4). Each pair of chromosomes is written using 
horizontal lines separated by semicolons, with the 1st chromosome being the sex chromosome 
(the Y is designated with a small diagonal hashmark). Since the 4th chromosome in Drosophila 
contains very little coding DNA, it is often omitted for the sake of convenience. Any mutations 
are written above or below the respective chromosomes, and the first letters of the dominant 
mutations are typically capitalized. Where multiple mutations are present on the same 
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chromosome, they are separated by a space. A cross between a female fly and a male fly is 
separated by an “x” symbol. 
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Figure 4: The above notation depicts a cross between a male, white-eyed fly (w1118) and a 
female white-eyed fly carrying a dominant Pin mutation on the second chromosome 
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Table 3: Fly strains used for genetic crosses 
 
Fly Strain 
notation 
Complete Genotype 
(Female notation used for convenience) 
Phenotypic Markers 
CS  External phenotype is wild-type 
APPL-GAL 4 
 
 Curly wings, red eyes,  tubby 
larva, additional bristles on 
thorax, x-shaped bristles along 
dorsal thorax 
ISH  Lobed eyes, x-shaped bristles 
along dorsal thorax, curly wings 
LEVY1  External phenotype is wild-type 
UAS-DJ1-α  External phenotype is wild-type 
UAS-LRRK2  External phenotype is wild-type 
UAS-PARKIN  External phenotype is wild-type 
UAS-PINK  Curly wings 
UAS-αSYN  External phenotype is wild-type 
FLY #3 
(Unnamed) 
 Curly wings, tubby larva, extra 
bristles on thorax, red eyes, lobed 
eyes, x-shaped bristles on dorsal 
thorax 
 
 
 
 
 
; ; 
; ;
Appl-Gal-4 
Appl-Gal-4 
Cyo Tb Antp 
Pin 
; ; 
Su(levy) L1 Pin 
CyO 
; ; 
levy 
levy 
; ; 
UAS-DJ1-α 
UAS-DJ1-α 
; ; 
UAS-hLRRK2 
UAS-hLRRK2 
; ; 
UAS-PARKIN 
UAS-PARKIN 
; ; 
UAS-PINK 
CyO 
; ; 
UAS-αSyn 
UAS-αSyn 
; ; 
Appl-Gal 4 
Su(levy) L1 Pin Appl-Gal 4 
CyO Tb Antp 
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Table 4: Specific AD and PD genes used for this research.  
 
Gene/Protein Fly Homolog Associated disease Protein function 
APP Appl/CG7727 AD Pre-synaptic protein 
Alpha-synuclein N/A PD Pre-synaptic protein 
Parkin parkin/CG10523 PD E3 ubiquitin ligase 
PINK1 pink1/CG4523 PD Mitochondrial kinase 
DJ-1 dJ-1α/CG6646 PD Redox sensor/Chaperone 
LRRK2 Lrrk2/CG5483 PD Kinase/GTPase 
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3.2 Crosses  
In order to test the effects of the Su(levy) on Drosophila neurodegeneration, it was 
necessary to perform crosses in order to combine flies carrying Su(levy) with flies carrying 
specific AD and PD mutations. This was done by crossing females containing APPL-GAL 4 
driver as well as Su(levy) mutation with males containing a specific responder controlled by an 
upstream activating sequence. The resulting progeny were selected for flies carrying APPL-
GAL-4 driver and the UAS-linked responder gene. In this case, the responder is expressed in 
neuronal tissue due to the neuronal expression of APPL-GAL-4 driver. Since multiple AD and 
PD mutations were used, it was necessary to generate a stable fly carrying both the driver and the 
Suppressor mutation, so that this fly could be mated to mutants and produce the desired progeny 
within one generation. The crosses utilized to obtain this stable line are shown in Figure 5.  
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Figure 5: Crosses used to obtain a stable heterozygous Su(levy) fly stock. The parental setup is 
shown at the top of each cross, with the selected progeny boxed in on the left, and the other 
progeny shown along the right. 
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Once a stable line containing the APPL-GAL-4 driver and the Suppressor of levy 
mutation was established, virgins from this line were mated to males carrying AD and PD 
mutations males and progeny were screened for the desired phenotypes. The flies collected were 
those that contained both the Su(levy) mutation as well as the respective AD or PD mutation 
along with the APPL-GAL-4 driver. An example of one of these crosses is shown in Figure 6. 
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Figure 6: An example of a cross to obtain flies carrying both Su(levy) mutation as well as a ND 
mutation. The parental cross is shown at the top. All progeny of this cross carry the GAL-4 
driver. The desired progeny carry the GAL-4 driver, as well as the responder gene (in this case α-
Syn, and Su(levy). The other progeny carry the GAL-4 driver and the responder gene, but not 
Su(levy). 
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In order to ensure the validity of the paternity for a given cross, it was necessary to isolate 
virgin flies of the genotype of interest. This was performed by emptying vials of all adults and 
collecting any newly eclosed females hatchlings within 8 hours. These females were isolated into 
a separate vial and aged for 7 days. After 7 days, the vial was screened for the presence of eggs 
and/or larvae. Once virginity was ensured (lack of eggs or larvae present), the flies were added to 
bottles with the males of interest. Female virgins were also collected by isolating and separating 
flies during the pupal stage. Late-stage pupa were collected with a brush and segregated into 
Eppindorf tubes capped with a moist cotton ball. Upon eclosion, females were used for crosses.  
 
3.3 Assays 
Mechanical and behavioral assays were chosen based on a variety of factors. The primary 
drivers for our research assays were the previously published literature and the availability of fly 
stocks and equipment in our lab. Since the hallmarks of neurodegeneration in animals are motor 
dysfunction, learning & memory impairment, and shortened lifespan, related assays were 
conducted. In most cases, protocols were borrowed from established literature with minor 
variations to suit the purpose of our experiments. 
 
Lifespan analysis: Flies used for lifespan analysis were raised at 25ºC and aged at 29 ºC 
. Newly eclosed males and females were segregated and placed in standard vials, 20 to a vial. 
Flies were counted each day. Vials were changed every 2-3 days and dead flies were counted and 
removed at time of transfer. The percent of surviving flies were graphed as a function of time. 
Flies that escaped during transfer or that died as a result of some other mitigating factor (getting 
stuck in the food) were not counted toward the lifespan data. 
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Bang-sensitivity assay: Bang sensitivity was performed on flies aged at 25ºC. Twenty-
day old flies were placed in empty plastic vials in groups of 10 and vortexed on high for 10 
seconds. This simulates mechanical trauma to the fly, and in many cases causes a fly to become 
paralyzed, or unable to move. After paralysis, the flies eventually regain motor function and 
begin moving. The length of time it took for flies to stand and walk around was recorded. The 
percentage of flies paralyzed was graphed as a function of time. 
 
Temperature-induced paralysis assay: Paralysis was performed at 38ºC. Flies were 
placed in clean, empty plastic vials, 10 to a vial. Vials were submerged in 38ºC water bath and 
the time taken by flies to paralyze was recorded. In this assay, paralysis was defined as the time 
when the fly took its last step and fell over onto its back. The percentage of flies paralyzed was 
graphed as a function of time. 
 
Locomotor assay: The climbing ability of flies is a direct indicator of motor skills and 
coordination. To test for climbing ability, 7-day old flies were placed ten to a vial, and a 
secondary vial was inverted and taped over the first vial. A line was drawn 8 cm up from the 
bottom of the first vial. Flies were allowed 10 minutes to acclimate to the surroundings. Flies 
were gently tapped to the bottom of the vial and the number of flies crossing the line after 10 
seconds was recorded. This was repeated five times with each grouping of ten flies, and the data 
were recorded as a percentage of successful flies.  
 
Drug sensitivity assay: Since many forms of human AD and PD are linked to 
environmental factors, it seemed worthwhile to test the ability of Su(levy) to suppress 
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neurodegenerative symptoms associated with exposure to environmental toxins. As such, we 
decided to compare the lifespan of both wild-type and Suppressor flies that were raised on 
normal food versus those that were raised on food laced with 500 µM Rotenone® (See Figure 
7). Rotenone® is a chemical that is widespread in pesticides, and has been linked to symptoms of 
PD in animals. All flies were grown at 25° C, and all other conditions were kept constant. We 
wanted to determine the phenotypic effects of exposure to this chemical, and whether or not 
Suppressor alleviated any of these symptoms.  
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Figure 7: Rotenone®, chemical formula C23H22O6, is a chemical commonly used in pesticides 
that has been linked to environmental forms of Parkinson’s disease 
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IV. Results 
Lifespan Analysis: Lifespan assays were run as separate replicates and the data were 
pooled and graphed as an overall survivorship percentage. Figure 8 shows the survivorship 
curves for wild-type, Su(levy), levy, and Su(levy) w/ levy. The median lifespan at 29°C for CS, 
Su(levy), levy, and Su(levy) w/levy was 26 days, 34 days, 9 days, and 12 days, respectively. 
Su(levy) mutation increased the median lifespan of levy flies and wild-type flies by 33% and 
31%, respectively. 
Figure 9 and Figure 10 show the survivorship curves for each of the six strains of flies 
carrying neurodegenerative mutations, as well as those strains of flies carrying the respective 
mutation alongside the Su(levy) mutation. In four out of the six cases, Su(levy) increased the 
median lifespan by a significant margin. In one case (Pink), Su(levy) decreased the lifespan by a 
significant margin, and in one case (Parkin), Su(levy) decreased lifespan, but not by a 
statistically significant amount. 
 Table 5 shows the median lifespan for each of the six strains mentioned above, as well as 
the changes in median lifespan when carrying the Su(levy) mutation. α-Syn, DJ 1-α, LRRK2, and 
αβ-42 flies each showed increases in lifespan of 22%, 32%, 23%, and 56%, respectively, when 
carrying the Su(levy) mutation. Pink and Parkin flies showed decreases in lifespan of 24% and 
7% respectively, when carrying the Su(levy) mutation. 
 A student’s T-test was run to determine if there was any statistically significant 
difference between the lifespan of the flies carrying the mutant gene and their counterparts 
carrying the mutant gene as well as Su(levy). The lifespan data of each fly tested for both strains 
was pooled and the average taken. The standard deviation was then calculated and a P-value of < 
0.05 was considered to be statistically significant (95 % confidence interval).  As a result, the 
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lifespan curves of CS, levy, α-Syn, DJ 1-α, Pink, LRRK, and αβ-42 were statistically significantly 
different from their Su(levy) counterparts. Based on these criteria, Parkin did not show 
statistically significant differences in lifespan curves (P value > 0.05). 
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Figure 8: Survivorship curves for CS, levy, Su(levy), and Su(levy) w/ levy flies. The Suppressor 
mutation increased the median lifespan of wild-type flies as well as that of levy flies exhibiting 
neurodegeneration.  
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Figure 9: Survivorship curves for CS, α-syn, α-syn w/ Su(levy), DJ 1-α, DJ 1-α w/ Su(levy), 
LRRK2, and LRRK2 w/ Su(levy) 
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Figure 10: Survivorship curves for CS, Pink, Pink w/ Su(levy), Parkin, Parkin w/ Su(levy), αβ-
42, and αβ-42 w/ Su(levy) 
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Table 5: Median lifespans and percent change in lifespan for mutant fly strains and mutant fly 
strains w/ Su(levy) mutation 
 
Fly Strain N value Median Lifespan Percent Change 
α-Syn 77 27  
α-Syn w/ Su(levy) 84 33 22% 
DJ 1-α 71 25  
DJ 1-α w/ Su(levy) 80 33 32% 
LRRK2 71 26  
LRRK2 w/ Su(levy) 108 32 23% 
Pink 75 25  
Pink w/ Su(levy) 71 19 (24%) 
Parkin 78 26  
Parkin w/ Su(levy) 73 24 (7%) 
αβ-42 120 18  
αβ-42 w/ Su(levy) 98 28 56% 
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Bang Sensitivity Assay: Neither CS flies nor Su(levy) flies showed any paralysis as a 
result of mechanical shock. They resumed normal flight and climbing behavior immediately after 
vortexing. Levy flies showed temporary paralysis as a result of vortexing. Levy flies took a 
median time of 6 seconds to recover from mechanical trauma and resume flight and climbing 
behavior. The shortest paralysis time was 2 seconds and the longest paralysis time was 50 
seconds. Figure 11 shows the bang-sensitivity of levy, CS, and Su(levy) flies, with the percent 
paralyzed graphed as a function of time. 
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Figure 11: Bang sensitivity of levy flies compared to wild-type flies. Levy flies took a median 
time of 6 seconds to recover from mechanical shock. Wild-type and Su(levy) flies showed no 
paralysis as a result of mechanical shock. 
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Temperature-Induced Paralysis: When exposed to 38°C, all strains of flies tested 
eventually became paralyzed. Paralysis was defined in this case as the point in time when the fly 
took its last step and fell over. The number of flies still standing was plotted as a function of time 
for each strain. Figure 12 displays the paralysis curves for wild-type, levy, Su(levy), and Su(levy) 
w/ levy, as well as the number of flies tested in each strain, and their median paralysis time. The 
median paralysis times for wild-type, levy, Su(levy), and Su(levy) w/ levy were 1254, 1447, 186, 
and 285 seconds, respectively.  
 Figures 13 and Figure 14 display the data for each of the AD and PD mutant fly strains 
tested. Each graph displays the wild-type fly as a control, as well as the flies carrying a 
neurodegenerative mutation, and finally those flies carrying the same neurodegenerative 
mutation as well as Su(levy). Table 6 displays the number of flies tested in each strain, the 
median paralysis times for each strain, and the percent change in median paralysis times. 
 A student’s T-test was used to determine if there was any statistically significant 
difference in the length of time it took for different strains of flies to paralyze. Each strain of fly 
carrying a mutation was compared to their counterparts carrying that mutation as well as 
Su(levy). The paralysis time for each fly was logged, and the average and standard deviation 
were determined. A P value of < 0.05 was considered to be statistically significant (95% 
confidence interval). The paralysis curves were found to be statistically different for each of the 
fly strains tested and their respective Su(levy) counterparts.  
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Figure 12: Temperature-induced paralysis for CS, Su(levy), levy, and Su(levy) w/ levy. The 
presence of Su(levy) increased the resistance of the flies to paralysis causing it to take 
significantly longer for them to paralyze at 38˚C. 
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Figure 13: Temperature-induced paralysis data for α-Synuclein and Aβ-42 flies, and their 
respective counterparts carrying Su(levy) mutation. 
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Figure 14: Temperature-induced paralysis data for LRRK2 and DJ 1-α flies, and their respective 
counterparts carrying Su(levy) mutation 
 
0
10
20
30
40
50
60
70
80
90
100
0 500 1000 1500 2000 2500
%
 N
o
t 
P
a
ra
ly
ze
d
Time (Seconds)
LRRK2 Paralysis
CS
hLRRK2
hLRRK2 w/ 
Su(levy)
0
10
20
30
40
50
60
70
80
90
100
0 500 1000 1500 2000 2500 3000
%
 N
o
t 
P
a
ra
ly
ze
d
Time (Seconds)
DJ 1-α Paralysis
CS
DJ1a
DJ1a w/ 
Su(levy)
51 
 
Table 6: Median paralysis times for flies carrying neurodegenerative mutations 
Fly Strain N value Median Time o Paralysis (Seconds) Percent Change 
CS 50 1254  
α-Syn 18 1223  
α-Syn w/ Su(levy) 16 1448 18% 
Aβ-42 24 784  
Aβ-42 w/ Su(levy) 19 1280 39% 
LRRK2 22 999  
LRRK2 w/ Su(levy) 23 1200 20% 
DJ 1-α 26 1412  
DJ 1-α w/ Su(levy) 35 1643 16% 
 
 
 
 
 
 
 
 
 
 
                  
52 
 
Locomotor Assay (Climbing Assay): Each strain of fly tested showed an increase in 
climbing ability when carrying the Su(levy) mutation with the degree of significance varying for 
each strain. Figure 15 displays the rate of climbing success for each strain of fly tested. The 
error bars show the variance associated with each test. There is a substantial amount of variance 
associated with this assay, and as a result the usefulness of these data is brought into question. 
For example, the average success rate of DJ 1-α flies is 75%, but the range of their success is 
from 61% to 90%. The fact that DJ 1-α w/ Su(levy) has an average success rate of 81% appears 
to show an overall improvement, but the significant amount of variance makes it hard to 
speculate. 
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Strain N Value 
DJ 1-α 567 
DJ 1-α w/ Su(levy) 850 
α-Syn 290 
α-Syn w/ Su(levy) 686 
hLRRK2 150 
hLRRK2 w/ Su(levy) 282 
CS 165 
CS w/ Su(levy) 179 
Aβ 56 
Aβ w/ Su(levy) 75 
             
 
 
 
Figure 15: Su(levy) flies showed better locomotor ability than their counterparts without 
Su(levy), but there is a high degree of variance. 
 
0
10
20
30
40
50
60
70
80
90
100
%
 S
u
cc
e
ss
fu
l
Locomotor Assay DJ1a
DJ1a w/ Su(levy)
A-Syn
A-Syn w/ Su(levy)
hLRRK2
hLRRK2 w/ Su(levy)
CS
CS w/ Su(levy)
A-B
A-B w/ Su(levy)
54 
 
Drug Sensitivity Assay: Regardless of the strain, flies reared on food laced with 
Rotenone® had a shorter median lifespan than flies reared on regular cornstarch medium. The 
Rotenone® seemed to have a less deleterious effect on Su(levy) flies, as their lifespan was 
slightly less affected by the drug. Su(levy) flies had a median lifespan decrease from 32 days to 
26 days, or 19% decrease. Wild-type flies had a median lifespan decrease from 25 days to 14 
days, or 44% decrease. There was a slightly greater degree of variance with this lifespan assay as 
compared with others, with the CS control fly showing the greatest degree of variance. Figure 
16 displays the median lifespan for wild-type and Su(levy) flies raised on regular food medium 
and those raised on medium laced with Rotenone®. 
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Figure 16: Lifespan of both wild-type and Su(levy) flies raised on regular food versus food laced 
with Rotenone®. While both flies showed a decrease in median lifespan, the effect was lessened 
in flies carrying Su(levy). 
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V. Discussion 
5.1 Suppressor of levy increases lifespan, locomotor function, resistance to mechanical shock, 
resistance to temperature-induced paralysis, and resistance to environmental toxins 
 
All fly progeny containing Su(levy) mutation showed an increased median lifespan when 
compared to their wild-type or mutant counterpart, with the exception of Pink and Parkin (see 
Table 5). The degree of change varied with the specific mutation, but it is interesting to note that 
in the cases of α-Syn, DJ 1-α, and LRRK2, the median lifespan w/ Su(levy) was roughly 33 days 
in each case. It is worth noting that in the case of Pink and Parkin, the flies containing the 
Su(levy) mutation actually showed a decrease in median lifespan. In these cases, the protein 
produced by Su(levy) may play a deleterious role in neuronal cells. While this data in itself does 
not support the rescue role of Su(levy) demonstrated  with other strains of flies, it does lend a 
degree of credence and validity to the experimental setup. For one thing, it demonstrates that 
there is not some other variable factor that is actually leading to the changes in lifespan.  If every 
fly strain containing Su(levy) tested showed  an increase in lifespan, one could not be sure that it 
was the mutation itself causing the change, as opposed to some other factor in the experimental 
design such as the GAL-4 construct, or the UAS sequence itself.  
These changes represent significant increases to the lifespan of Drosophila. The average 
increase in lifespan across fly strains was roughly 30%. Extrapolated to a human model, it is the 
equivalent of a person’s longevity increasing from 60 years to 78 years. Since both AD and PD 
are characterized by reduced lifespan, these results are very promising.  
A major hallmark of neurodegenerative disorders in humans is a decrease in motor 
activity and coordination. This manifests itself in Drosophila via a decreased ability to climb the 
walls of a vial. When crossed with Su(levy), all PD and AD mutants showed a markedly better 
ability to climb than their counterpart flies that only contained the ND mutation. This provides 
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evidence for the notion that Su(levy) is somehow relieving motor dysfunction associated with 
ND. All fly progeny containing Su(levy) mutation showed improved climbing ability when 
compared to their mutant or wild-type counterpart. There was substantial statistical variance in 
this assay (see Figure 15), making it difficult to say just how much of a role Su(levy) was 
playing. It is interesting to note that all flies had a success rate of between 71-81% when carrying 
the Suppressor mutation, regardless of the AD or PD gene that they carried. It would seem that 
Su(levy) rescues locomotor function to somewhat of a “baseline” without regard for how 
dysfunctional the locomotor ability is to begin with. Further research is necessary to verify this 
hypothesis. 
When exposed to an increase in temperature, flies expressing AD and PD genes show a 
greater tendency to become paralyzed more quickly than wild-type flies. However, progeny 
expressing a ND gene as well as Su(levy) show improved resistance to paralysis than their 
counterparts expressing only the ND gene. Since temperature-induced paralysis is a direct 
measure of motor function, the fact that the results are analogous to the results of the locomotor 
test is promising. This indicates that perhaps Suppressor is acting in a similar fashion in both 
cases. 
It is difficult to speculate on how Su(levy) may alleviate temperature-induced paralysis. It 
is known that levy flies show reduced COX activity. However, the pathway from reduced COX 
activity to neurodegeneration is not known. Su(levy) most probably functions in this pathway or 
an interacting pathway, and it is important to identify the suppressor gene to determine how 
exactly it is operating. 
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Environmental toxins have been linked to neurological disorders in humans [47]. As 
mentioned above, much current research suggests mitochondrial dysfunction as a major culprit in 
idiopathic cases of AD and PD. Environmental toxins have been shown to generate the afore-
mentioned reactive oxygen species (ROS), which interfere with proper mitochondrial function. 
In humans, these environmental toxins include things commonly found in pesticides, herbicides, 
and fungicides; two of the most common culprits being Benomyl and Rotenone®. 
In Drosophila, as in humans, there are a variety of toxins linked to motor dysfunction, 
reduced lifespan, and coordination deficits. Research has shown strong correlation between 
exposure to toxins and reduced lifespan and locomotor ability. The most well-studied toxins in 
Drosophila are Rotenone, Paraquat, and hydrogen peroxide [47]. 
Our results showed that Suppressor of levy mutation reduced the effects of Rotenone® on 
Drosophila lifespan, when compared to wild-type flies. Again, this is very promising data, with 
the implication being that the presence of Suppressor of levy is reducing the impact of said 
environmental toxin on the nervous system of Drosophila. The fact that Su(levy) flies that had 
been fed Rotenone showed a markedly smaller reduction in lifespan when compared to CS flies 
that had been fed Rotenone is promising. The common thread between many of these rescue-
type behaviors seems to be the role of biochemical pathways in the mitochondria.  
 
5.2 Suppressor of levy may play a role in biochemical pathways in the mitochondria 
 The underlying biochemistry behind the action of Su(levy) has not yet been investigated, 
so it is difficult to draw conclusions about its mechanisms of action. However, based on what is 
known about levy, and the data that has been accumulated, it is worthwhile to speculate. It has 
long been known that oxidative stress associated with mitochondrial function can plays a key 
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role in human neurodegenerative conditions [21]. Specifically, reactive oxygen species tend to 
interact with electron transport chains and damage membrane proteins, which subsequently 
accumulate and crosslink to other proteins, inhibiting biochemical function [46]. This oxidative 
stress significantly reduces the overall life of the cell [46].  
Previous work on the levy mutation showed that flies carrying the levy gene had markedly 
reduced cytochrome c oxidase (COX) activity [33]. It was suggested that this reduction in COX 
activity was not due to a decrease in overall number of mitochondria, but rather a reduction in 
the enzymatic activity of the cytochrome itself [33]. This subsequently leads to the 
neurodegeneration prevalent in levy flies. It is unknown whether the Su(levy) mutation is coding 
for a dysfunctional gene product, or whether it produces no gene product at all. However, based 
on the behavior of Su(levy) flies, one could speculate that it is this lack of functional gene 
product that inhibits the oxidative action of free radicals in the mitochondria. 
 It is worthwhile to note that a characteristic feature of ND in human patients is 
accumulation of amyloid protein aggregates and neurofibrillary tangles that occur through the 
aforementioned oxidative stress [46]. Also, the content of carbonyl groups in the brain of human 
AD patients is significantly higher than those in similar-aged controls. It is very likely that 
Su(levy) is blocking the accumulation and buildup of these aggregates either by a) specifically 
interacting with ROS and blocking their oxidative ability, or b) preventing the accumulation of 
tangles and peptides once the oxidatively damaged proteins have been formed. A worthwhile 
assay would be to perform a carbonyl assay on levy and Su(levy) flies to determine if there is a 
significant difference in accumulation, which may lend credence to this method of action. 
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5.3 Suppressor of levy may play a general protective role in Drosophila 
Our preliminary data supports the notion that Suppressor of levy plays a significant role 
in alleviating neurodegenerative symptoms in Drosophila. For most of the flies tested, Su(levy) 
increased lifespan, reduced motor deficit, and protected from paralysis to varying degrees. This 
leads to the possibility that it is not a gene-specific suppressor, but rather might act in a non-
specific manner to mitigate neurodegeneration. Suppressor of levy should be tested with other 
mutant strains of flies exhibiting ND to determine if this trend holds true. 
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VI. Summary and Future Work 
6.1 Identification and sequencing of Suppressor gene 
In order to gain any understanding of the underlying mechanisms behind how Su(levy) 
relieves ND, the gene must be identified and subsequently sequenced. Previous work in the lab 
has already identified some candidate genes for this mutation. The next logical step would be to 
sequence these gene regions from a Su(levy) fly, a levy fly, and a CS fly, to determine the 
specific regions of dissimilarity. Once the Su(levy) gene is identified, it would open the door to 
pursue experiments that will allow a much greater understanding of the how the gene is working. 
 
6.2 Potential therapeutic implications 
The ultimate goal of this research is to identify the underlying mechanisms behind human 
AD and PD. Once these mechanisms are known, improved therapeutic treatments can be 
pursued. If the dysfunctional gene product (or lack of product altogether) coded for by the 
Su(levy) gene mutation is identified as inhibiting neurodegenerative symptoms in a Drosophila 
model, it may have analogous behavior in a mammalian model. From a pharmacological 
perspective, it may be possible to synthesize a drug that mimics this behavior, with potential 
treatment applications in humans. Continued research on this gene may uncover therapeutic 
implications for human neurodegenerative conditions. 
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